.png){kind=icon}
.png){kind=icon}
Return
Gut microbiota and the gut–liver axis in MASLD: mechanisms; immune regulation and therapeutic opportunities
.png){kind=icon}
OA
AI
J
M
S
C
Y
Y
DOI：10.3389/fphar.2026.1917467.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the most common chronic liver diseases worldwide; affecting more than one-third of adults and imposing a substantial hepatic and systemic metabolic burden. With the continuing rise in obesity; type 2 diabetes mellitus; and related metabolic abnormalities; the prevalence of MASLD is expected to keep increasing. This review summarizes MASLD from the overarching perspective of gut-liver axis dysregulation; focusing on alterations in gut microbial composition and function; intestinal barrier injury; disturbances in microbiota-derived metabolites; and gut microbiota-associated epigenetic and immune dysregulation during disease initiation and progression. It further integrates the overall significance of these changes in the evolution of MASLD. Finally; potential therapeutic strategies represented by fecal microbiota transplantation and natural products are briefly discussed; suggesting that targeting the gut microbiota and its related networks may provide new opportunities for MASLD prevention and treatment.
Keywords:
gut microbiota
metabolic dysfunction-associated steatotic liver disease
immune regulation
microbial metabolites
medicine
Journal
IF:
4.8
Papers:
5.7K
Citations:
10.6W
Organization
No organization information available
Cited Papers